December 14, 2020 11:04 AM ESTUpdated 02:31 PM

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO

Max Gelman

Senior Editor

Conner Mitchell

Arvinas $ARVN has new data out on two of its protein degrader programs, and investors seemed thrilled with the news Monday morning as shares doubled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO

Max Gelman

Senior Editor

Conner Mitchell

Sign up to read this article for free.

Roche no longer wants to be where ‘DNA sequencing goes to die’

Trump’s HHS defends drug price negotiations in Novartis suit

First meeting of CDC vaccine advisors in the Kennedy era is postponed

Drug packaging manufacturers brace for impact as EU chemical ban looms

How Keymed steered the China-to-US NewCo model in biotech

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

News brief­ing: Arv­inas shares dou­ble on in­ter­im da­ta for two can­cer pro­grams; UK bio­phar­ma snaps up on­col­o­gy CRO

Senior Editor

Sign up to read this article for free.

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO